Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Lorenzoni

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|July 23, 2015
Pap smear in the prevention of HPV-related anal cancer: preliminary results of the study in a male population at riskLuigi Pisano, Luana Tiradritti, Elisa Lorenzoni, et al.
Dermatologic Therapy|August 7, 2013
Jessner-Kanof disease: two effective and sure therapeutic optionsRossana Conti, Andrea Bassi, Elisa Lorenzoni, et al.
Dermatology Practical & Conceptual|November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Italian Journal of Dermatology and Venereology|November 7, 2024
Risankizumab in very elderly patients in real-world practiceElisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|July 23, 2015
Pap smear in the prevention of HPV-related anal cancer: preliminary results of the study in a male population at riskLuigi Pisano, Luana Tiradritti, Elisa Lorenzoni, et al.
Dermatologic Therapy|August 7, 2013
Jessner-Kanof disease: two effective and sure therapeutic optionsRossana Conti, Andrea Bassi, Elisa Lorenzoni, et al.
Dermatology Practical & Conceptual|November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Italian Journal of Dermatology and Venereology|November 7, 2024
Risankizumab in very elderly patients in real-world practiceElisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Pageof 1